Company profile: Standard Bariatrics
1.1 - Company Overview
Company description
- Provider of surgical instruments for weight-loss surgeries, focused on sleeve gastrectomy. Offerings include Titan SGS, a surgical stapler with a 23 cm continuous staple line for consistent sleeve anatomy; Standard Precision Bougie Device for precise alignment and protection of the incisura angularis; Standard Trocar, a bladeless access device for introducing Titan SGS; and Standard Clamp to plan and hold the staple line, helping standardize technique and improve efficiency.
Products and services
- Titan SGS: Sleeve-gastrectomy-specific surgical stapler engineered to deliver a 23cm continuous staple line, supporting consistent sleeve anatomy during sleeve gastrectomy
- Standard Clamp: Laparoscopic device that clamps the entire stomach length to aid planning and hold the staple line before division, helping standardize techniques, reduce variation, improve efficiency, and eliminate waste
- Standard Precision Bougie Device: Sleeve-gastrectomy-specific component architects precise anatomical alignment and protects the incisura angularis, assisting surgeons in maintaining accurate sleeve anatomy during the procedure
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Standard Bariatrics
Calliditas Therapeutics
HQ: Sweden
Website
- Description: Provider of specialty pharmaceuticals for unmet medical needs in niche indications, including TARPEYO (delayed-release budesonide for renal diseases), Kinpeygo (renal and hepatic diseases), NEFECON (candidate for primary IgA nephropathy), and Setanaxib (NOX1/4 inhibitor in trials for PBC and head & neck cancer), plus pipeline development for orphan renal/hepatic diseases and strategic partnerships for development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calliditas Therapeutics company profile →
QOL Medical
HQ: United States
Website
- Description: Provider of specialty biopharmaceutical products and services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QOL Medical company profile →
Baronova
HQ: United States
Website
- Description: Provider of clinical-stage medical devices under development to induce weight loss through non-surgical, non-pharmacologic approaches.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Baronova company profile →
Theratechnologies
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies, including Trogarzo for HIV in individuals with limited treatment options due to resistance, intolerance, or safety considerations; EGRIFTA SV (tesamorelin) to reduce excess abdominal fat in HIV patients with lipodystrophy; and Long Acting Peptides and the SORT1+ oncology platform. Pipeline includes tesamorelin for NASH, F8 bioequivalent formulation, and a multi-dose pen injector in development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theratechnologies company profile →
XOMA
HQ: United States
Website
- Description: Provider of biotech royalty aggregation through acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies, supported by a royalty portfolio of licenses; also provider of antibody discovery and development via a phage display platform, with developing assets including ebopiprant and an anti-prolactin antibody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XOMA company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Standard Bariatrics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Standard Bariatrics
2.2 - Growth funds investing in similar companies to Standard Bariatrics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Standard Bariatrics
4.2 - Public trading comparable groups for Standard Bariatrics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →